ArticleCancer immunology, immunotherapy : CII2025
Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- CT semantic features of primary gastric cancer: a preoperative predictive model for peritoneal metastasis with superior efficacy to conventional direct CT assessment.BMC gastroenterology · 2026Article
- Conversion Surgery for Advanced Gastric Cancer with Para-Aortic Lymph Node Metastases Following Treatment with Capecitabine, Oxaliplatin, and Pembrolizumab: A Case Report.Surgical case reports · 2026Article
- From Control to Conversion: Optimizing Systemic Therapy for Curative-Intent Conversion Surgery in Metastatic Gastric Cancer.Journal of gastric cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.
methodsData from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group. The survival outcomes between the two groups and the potential biomarkers that may predict the effectiveness of combining PD-1 inhibitors with chemotherapy were analyzed.
resultsA total of 105 patients were included in the analysis, with 48 patients in the surgery group and 57 patients in the palliative group, resulting in a conversion rate of 45.7%. R0 resection was performed in 40 patients (83.3%) in the surgery group. The median survival time (MST) was not reached in the surgery group, while it was 12.0 months in the palliative group (P < 0.001). There were significant differences in 1-year and 3-year overall survival (OS) between the two groups (1-year OS: 93.7% vs. 45.6%, P < 0.001; 3-year OS: 52.1% vs. 4.0%, P < 0.001). Subgroup analysis revealed that patients with PD-L1 CPS ≥ 1 had significantly higher overall response rates (62.5% vs. 38.5%, P = 0.016) and conversion rates (60.4% vs. 32.7%, P = 0.005). For patients with peritoneal metastasis, a significant survival benefit was observed in those who received HIPEC treatment compared to those who did not (MST: 18.0 months vs. 9.0 months, P = 0.039). The incidence of treatment-related adverse events was similar to previous observations, with no new safety signals identified.
conclusionsThe combination of PD-1 inhibitors with chemotherapy in conversion therapy is feasible for patients with stage IV gastric cancer. Individuals who exhibit improved responses to chemoimmunotherapy potentially experience survival benefits, particularly those with PD-L1 positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.